Illumina reaffirms annual revenue forecast over continued sluggish demand
May 2 (Reuters) -Illumina ILMN.O reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.
The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers.
The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this year compared with 2023, and still sees its adjusted operating margin to be about 20%.
The company said it is on track to divest cancer diagnostic test maker Grail GRAL.O and expects to finalize terms by the second quarter.
U.S. life sciences Illumina's first-quarter revenue was $1.08 billion, above analysts' estimate of $1.05 billion.
On an adjusted basis, it earned profit of 9 cents per share in the quarter ended March 31, narrowly beating analysts' average estimate of 4 cents per share.
Shares of the company fell to 2.4% at $121 in aftermarket trading.
Reporting by Unnamalai L in Bengaluru; Editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
